Table 2.
Hepatocellular carcinoma age-standardised incidence and incidence-based mortality rates 1997–2017, by nation, sex, subtype, and year.
| Incidence | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UK |
England |
Scotland |
Wales |
Northern Ireland |
|||||||||||
| N cases | ASR | 95% CI | N cases | ASR | 95% CI | N cases | ASR | 95% CI | N cases | ASR | 95% CI | N cases | ASR | 95% CI | |
| Persons | |||||||||||||||
| 1997 | 884 | 1.82 | (1.70–1.94) | 672 | 1.66 | (1.53–1.79) | 145 | 3.40 | (2.87–4.00) | 53 | 2.00 | (1.50–2.62) | 14 | 1.19 | (0.65–2.00) |
| 2007 | 1,873 | 3.54 | (3.38–3.71) | 1,469 | 3.33 | (3.16–3.50) | 243 | 5.24 | (4.6–5.95) | 106 | 3.74 | (3.06–4.53) | 55 | 4.21 | (3.17–5.49) |
| 2017 | 3,368 | 5.45 | (5.27–5.64) | 2,711 | 5.25 | (5.05–5.45) | 409 | 7.71 | (6.98–8.50) | 169 | 5.23 | (4.47–6.08) | 79 | 4.95 | (3.92–6.17) |
| Men | |||||||||||||||
| 1997 | 647 | 3.03 | (2.80–3.28) | 487 | 2.73 | (2.49–2.99) | 111 | 5.99 | (4.91–7.24) | 40 | 3.55 | (2.53–4.84) | 9 | 1.75 | (0.79–3.35) |
| 2007 | 1,449 | 6.04 | (5.73–6.37) | 1,128 | 5.63 | (5.31–5.98) | 199 | 9.71 | (8.38–11.19) | 80 | 6.12 | (4.84–7.62) | 42 | 7.13 | (5.10–9.68) |
| 2017 | 2,643 | 9.22 | (8.87–9.58) | 2,127 | 8.87 | (8.49–9.26) | 321 | 13.31 | (11.87–14.87) | 131 | 8.62 | (7.20–10.24) | 64 | 8.66 | (6.65–11.08) |
| Women | |||||||||||||||
| 1997 | 237 | 0.87 | (0.77–0.99) | 185 | 0.82 | (0.70–0.95) | 34 | 1.43 | (0.99–2.00) | 13 | 0.87 | (0.46–1.50) | 5 | 0.72 | (0.23–1.67) |
| 2007 | 424 | 1.45 | (1.31–1.59) | 341 | 1.39 | (1.25–1.55) | 44 | 1.73 | (1.25–2.32) | 26 | 1.66 | (1.08–2.45) | 13 | 1.78 | (0.94–3.05) |
| 2017 |
725 |
2.17 |
(2.02–2.34) |
584 |
2.09 |
(1.92–2.27) |
88 |
3.08 |
(2.47–3.80) |
38 |
2.19 |
(1.54–3.01) |
15 |
1.80 |
(1.01–2.98) |
| Incidence-based mortality | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UK |
England |
Scotland |
Wales |
Northern Ireland |
|||||||||||
| N cases | ASMR | 95% CI | N cases | ASMR | 95% CI | N cases | ASMR | 95% CI | N cases | ASMR | 95% CI | N cases | ASMR | 95% CI | |
| Persons | |||||||||||||||
| 1999 | 657 | 1.33 | (1.23–1.44) | 520 | 1.26 | (1.16–1.38) | 82 | 1.95 | (1.55–2.42) | 43 | 1.63 | (1.18–2.20) | 12 | 1.01 | (0.52–1.77) |
| 2007 | 1,278 | 2.44 | (2.30–2.57) | 987 | 2.26 | (2.12–2.40) | 184 | 3.96 | (3.41–4.58) | 72 | 2.56 | (2–3.22) | 35 | 2.74 | (1.90–3.82) |
| 2017 | 2,456 | 3.98 | (3.82–4.14) | 1,953 | 3.79 | (3.62–3.96) | 323 | 6.12 | (5.47–6.83) | 131 | 4.01 | (3.35–4.75) | 49 | 3.08 | (2.27–4.07) |
| Men | |||||||||||||||
| 1999 | 463 | 2.11 | (1.92–2.32) | 372 | 2.01 | (1.81–2.23) | 56 | 3.16 | (2.34–4.17) | 26 | 2.24 | (1.45–3.29) | 9 | 1.75 | (0.77–3.37) |
| 2007 | 992 | 4.19 | (3.93–4.46) | 764 | 3.87 | (3.59–4.15) | 149 | 7.29 | (6.14–8.58) | 52 | 4.01 | (2.99–5.27) | 27 | 4.72 | (3.09–6.90) |
| 2017 | 1,918 | 6.74 | (6.44–7.05) | 1,528 | 6.41 | (6.09–6.74) | 244 | 10.33 | (9.05–11.73) | 106 | 6.96 | (5.69–8.43) | 40 | 5.55 | (3.95–7.57) |
| Women | |||||||||||||||
| 1999 | 194 | 0.69 | (0.60–0.80) | 148 | 0.64 | (0.54–0.75) | 26 | 1.04 | (0.68–1.52) | 17 | 1.12 | (0.65–1.8) | 3 | 0.44 | (0.09–1.28) |
| 2007 | 286 | 0.99 | (0.88–1.11) | 223 | 0.92 | (0.80–1.05) | 35 | 1.37 | (0.95–1.91) | 20 | 1.31 | (0.80–2.03) | 8 | 1.14 | (0.49–2.25) |
| 2017 | 538 | 1.61 | (1.48–1.76) | 425 | 1.53 | (1.38–1.68) | 79 | 2.74 | (2.17–3.42) | 25 | 1.41 | (0.91–2.09) | 9 | 1.05 | (0.48–2.00) |
ASMR, age-standardised mortality rate; ASR, age-standardised incidence rate.